Québec City, July 24, 2015 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Corporation”) an innovator in sterilization technology for medical devices in healthcare settings, today announced the appointment of Mrs. Elena Simard-Veilleux, CPA, CA to the position of Interim Chief Financial Officer effective immediately. Mrs. Simard-Veilleux replaces Mr. Benoît Deschamps who had held the position for the past four years. Mr Deschamps has elected to pursue other professional activities outside the Company.
“Elena has been a key contributor to the organization for the past four years and had been TSO3’s Corporate Controller and Assistant Company Secretary for the past three years. I look forward to her continued contribution to the Company with this increased responsibility. Simultaneously, I would like to thank and acknowledge Benoit’s contribution to the Company these past four years and offer him my sincere well wishes in his future endeavours” stated R.M. (Ric) Rumble, President and CEO of TSO3.
Founded in 1998, TSO3’s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company’s Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
-30-Back to Posts